Atossa Genetics, Inc. 2014 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014. The source filing identifies the registrant as Atossa Genetics, Inc.; the request metadata refers to Atossa Therapeutics, Inc. The company is a healthcare business developing breast-health laboratory services, medical devices and potential therapeutics through its wholly owned NRLBH subsidiary.
Business context
- NRLBH marketed nipple aspirate fluid cytology and pharmacogenomics testing. The pharmacogenomics test launched in October 2014 and processed 527 tests through year-end.
- The FullCYTE Breast Aspirator was FDA-cleared for U.S. NAF collection; the ForeCYTE Breast Aspirator was CE-marked for European and EFTA markets but was not FDA-cleared for U.S. marketing.
- FullCYTE and ForeCYTE launches occurred in March 2015, after the reporting period. NextCYTE, ArgusCYTE, microcatheters and therapeutic programs remained under development.
Key financial metrics
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Total revenue | $525,954 | $632,558 | Down 17% |
| Gross profit | $185,296 | $137,093 | Up 35% |
| Gross margin | Approximately 35.2% | Approximately 21.7% | Improved |
| Operating loss | $(14,642,417) | $(10,784,643) | Loss increased |
| Net loss | $(14,657,926) | $(10,784,708) | Loss increased 36% |
| Loss per share | $(0.61) | $(0.70) | Improved on higher share count |
| Cash used in operating activities | $(10,555,450) | $(8,830,044) | Use increased |
| Cash and cash equivalents | $8,500,718 | $6,342,161 | Increased |
| Working capital | Approximately $6.9 million | Not clearly provided in the filing text | — |
| Total liabilities | $2,265,875 | $1,407,396 | Increased |
| Accumulated deficit | $(35,174,540) | $(20,516,614) | Expanded |
Revenue consisted entirely of diagnostic testing service revenue in 2014; the filing reports no product sales. Substantially all 2014 revenue was recognized in the fourth quarter after the pharmacogenomics test launch. Cost of revenue was $340,658, producing gross profit of $185,296. The filing does not provide a clear quarterly revenue or quarterly loss breakdown.
Operating expenses totaled $14,827,713, including $8,625,917 of general and administrative expense, $2,577,465 of research and development expense, $1,271,705 of selling expense and a $2,352,626 impairment charge related to Acueity intangible assets. The company had no income tax benefit despite approximately $28.7 million of federal net operating loss carryforwards because a full valuation allowance was recorded.
The filing does not identify conventional interest-bearing debt as a material financing source. Liabilities included short- and long-term lease obligations of $125,241 in aggregate, along with operating lease commitments of $1,123,688 through 2019. The company also had contractual purchase commitments, including $452,408 annually under the Luminex agreement and remaining Affymetrix array commitments.
Material changes versus 2013
- Revenue declined 17% because the 2013 MASCT/ForeCYTE product recall halted product-related revenue from October 2013 through most of 2014. Revenue shifted to pharmacogenomics testing.
- Product sales fell from $223,440 to zero, while diagnostic testing service revenue increased from $409,118 to $525,954.
- Gross margin improved because 2013 included product costs and a $149,946 obsolete-inventory charge related to the recall.
- R&D expense increased 133% to $2.6 million as the company advanced NextCYTE, microcatheters, FullCYTE and other pipeline programs.
- The company recorded a $2.4 million impairment charge on Acueity-related intangible assets after delaying further development and investment in those assets.
- Cash increased primarily because of financing proceeds, including approximately $14.0 million from a January 2014 public offering of units containing common stock and warrants. Common shares outstanding increased to 24,564,058 from 18,574,334.
- Operating cash burn increased by approximately $1.7 million to $10.6 million.
Guidance, outlook, risks and unusual items
- Management expected to launch and commercialize FullCYTE in the United States and ForeCYTE in selected European markets in 2015, expand laboratory testing revenue and begin clinical studies related to potential therapies.
- Management stated that existing resources were expected to fund planned operations for only four to eight months after December 31, 2014, absent additional capital. The financial statements include an explicit substantial-doubt going-concern disclosure.
- Potential funding sources included equity sales, the Aspire Capital purchase agreement, registered securities offerings and possible borrowings. Through March 27, 2015, the company sold 832,066 shares to Aspire for approximately $1.54 million.
- Commercial success depends on physician and patient adoption, reimbursement, pricing, third-party manufacturing, sales execution and regulatory clearances. Medicare and certain insurers did not reimburse the NAF collection procedure, although laboratory analysis could be reimbursed.
- FDA regulatory risk remained significant. The FDA determined in September 2014 that ForeCYTE was not substantially equivalent to its predicate device for U.S. marketing. The company could not market ForeCYTE in the United States without additional clearance.
- The FDA closed its follow-up inspection in December 2014, but future inspections and regulatory actions remained possible. The company also disclosed evolving FDA oversight of laboratory-developed tests.
- A securities class action dismissed by the trial court was on appeal as of the filing date. The company recorded no liability because the potential loss could not be reasonably estimated.
- The company recorded a $2,352,626 intangible-asset impairment and continued to incur substantial stock-based compensation, totaling $698,657 in 2014.
Investor verification checklist
- Verify current liquidity, monthly cash burn and whether subsequent equity financings were sufficient to address the disclosed four-to-eight-month funding horizon.
- Verify the status and commercial adoption of FullCYTE and ForeCYTE, including product volumes, pricing, gross margins and distributor performance.
- Verify FDA clearance prospects for ForeCYTE in the United States and the continuing status of FDA quality-system and laboratory-developed-test requirements.
- Verify reimbursement coverage, medical-necessity policies and realized collection rates for pharmacogenomics and NAF testing.
- Review dilution from the Aspire agreement, outstanding warrants and stock options; as of December 31, 2014, warrants to purchase 6,033,426 shares and options to purchase 3,675,634 shares were outstanding.
- Review the going-concern disclosure, lease and purchase commitments, and the company’s ability to fund planned R&D and commercialization activities.
- Check the subsequent status and potential financial impact of the securities litigation appeal and any other regulatory or product-liability matters.